CN102782497A - 测定 - Google Patents

测定 Download PDF

Info

Publication number
CN102782497A
CN102782497A CN2010800568880A CN201080056888A CN102782497A CN 102782497 A CN102782497 A CN 102782497A CN 2010800568880 A CN2010800568880 A CN 2010800568880A CN 201080056888 A CN201080056888 A CN 201080056888A CN 102782497 A CN102782497 A CN 102782497A
Authority
CN
China
Prior art keywords
mensuration
sample
polypeptide
psa
mcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800568880A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·拉斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytosystems Ltd
Original Assignee
Cytosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosystems Ltd filed Critical Cytosystems Ltd
Publication of CN102782497A publication Critical patent/CN102782497A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2010800568880A 2009-12-15 2010-12-15 测定 Pending CN102782497A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0921873.6 2009-12-15
GBGB0921873.6A GB0921873D0 (en) 2009-12-15 2009-12-15 Assay
PCT/GB2010/002274 WO2011073619A1 (en) 2009-12-15 2010-12-15 Assay

Publications (1)

Publication Number Publication Date
CN102782497A true CN102782497A (zh) 2012-11-14

Family

ID=41667106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800568880A Pending CN102782497A (zh) 2009-12-15 2010-12-15 测定

Country Status (7)

Country Link
US (2) US20130171662A1 (https=)
EP (2) EP2513651A1 (https=)
JP (1) JP2013513812A (https=)
CN (1) CN102782497A (https=)
CA (1) CA2807870A1 (https=)
GB (1) GB0921873D0 (https=)
WO (1) WO2011073619A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4060344A1 (en) * 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
GB201820868D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CN101239181A (zh) * 2007-02-08 2008-08-13 中国科学院上海生命科学研究院 一种和癌症有关的组蛋白去甲基化酶及其应用
WO2009050461A1 (en) * 2007-10-15 2009-04-23 Cambridge Cancer Diagnostics Limited Diagnostic, predictive and prognostic testing for cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6303323B1 (en) * 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
JP2000511291A (ja) * 1997-10-21 2000-08-29 キャンサー リサーチ キャンペーン テクノロジー リミティド 細胞の増殖異常の測定
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6566130B1 (en) * 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20060211059A1 (en) * 2005-03-18 2006-09-21 Taneja Samir S Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone
GB0800311D0 (en) 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
CN101239181A (zh) * 2007-02-08 2008-08-13 中国科学院上海生命科学研究院 一种和癌症有关的组蛋白去甲基化酶及其应用
WO2009050461A1 (en) * 2007-10-15 2009-04-23 Cambridge Cancer Diagnostics Limited Diagnostic, predictive and prognostic testing for cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B REN ET AL.: "MCM7 amplification and overexpression are associated with prostate cancer progression", 《ONCOGENE》, vol. 25, no. 7, 1 February 2006 (2006-02-01), pages 1090 - 1098, XP009122539, DOI: doi:10.1038/sj.onc.1209134 *
CLAUDE LABRIE ET AL: "Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases", 《UROLOGY》, vol. 69, no. 1, 31 January 2007 (2007-01-31), pages 196 - 201, XP005864502, DOI: doi:10.1016/j.urology.2006.11.001 *
KAI STOEBER ET AL。: "Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments", 《JOURNAL OF THE NATIONAL CANCER INSTITUTE》, vol. 94, no. 14, 17 July 2002 (2002-07-17), pages 1071 - 1079, XP009122537, DOI: doi:10.1093/jnci/94.14.1071 *
KAZUTOSHI FUJITA MD ET AL: "Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology", 《HUMAN PATHOLOGY》, vol. 40, no. 7, 1 July 2009 (2009-07-01), pages 924 - 933, XP026168727, DOI: doi:10.1016/j.humpath.2009.01.004 *
NARICULAM J. ET AL.: "MCM-2 EXPRESSION IN CLINICALLY LOCALISED PROSTATE CANCER", 《EUROPEAN UROLOGY SUPPLEMENTS》, vol. 7, no. 3, 1 March 2008 (2008-03-01), pages 255, XP022610736, DOI: doi:10.1016/S1569-9056(08)60736-8 *
NARICULAM J. ET AL.: "MCM-2 EXPRESSION IN CLINICALLY LOCALISED PROSTATE", 《EUROPEAN UROLOGY SUPPLEMENTS》, vol. 7, no. 3, 31 March 2008 (2008-03-31), pages 255, XP022610736, DOI: doi:10.1016/S1569-9056(08)60736-8 *
OUTI SARAMAKI AND TAPIO VISAKORPI: "Chromosomal aberrations in prostate cancer", 《FRONTIERS IN BIOSCIENCE》, vol. 12, 1 May 2007 (2007-05-01), pages 3287 - 3301, XP007906801, DOI: doi:10.2741/2312 *
V PADMANABHAN ET AL.: "DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer", 《JOURNAL OF CLINICAL PATHOLOGY》, vol. 57, no. 10, 1 October 2004 (2004-10-01), pages 1057 - 1062, XP002506509, DOI: doi:10.1136/JCP.2004.016436 *

Also Published As

Publication number Publication date
GB0921873D0 (en) 2010-01-27
US20150219659A1 (en) 2015-08-06
US10267801B2 (en) 2019-04-23
JP2013513812A (ja) 2013-04-22
WO2011073619A1 (en) 2011-06-23
US20130171662A1 (en) 2013-07-04
EP2977762A3 (en) 2016-05-04
EP2513651A1 (en) 2012-10-24
CA2807870A1 (en) 2011-06-23
EP2977762A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
US20210047697A1 (en) Method for improved diagnosis of dysplasias
US9618512B2 (en) Biomarker for breast cancer
CN106415269A (zh) 直接免疫组织化学测定
US9625461B2 (en) Method of detecting cancer using delta-catenin
CN101669032A (zh) 通过膜联蛋白a3对前列腺癌症的自身免疫调节
US10267801B2 (en) Assay
US10145850B2 (en) Assay
CN112236677A (zh) 直接免疫组织化学和免疫细胞化学方法
CN111208304A (zh) 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途
EP3124974A1 (en) Method for the normalization of immunological tests and kits for performing such tests

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121114